These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8061720)

  • 1. Pattern analysis method for assessing successful weight reduction.
    Holman SL; Goldstein DJ; Enas GG
    Int J Obes Relat Metab Disord; 1994 May; 18(5):281-5. PubMed ID: 8061720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data.
    Sayler ME; Goldstein DJ; Roback PJ; Atkinson RL
    Int J Obes Relat Metab Disord; 1994 Nov; 18(11):742-51. PubMed ID: 7866474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
    Van Gaal LF; Caterson ID; Coutinho W; Finer N; Maggioni AP; Sharma AM; Torp-Pedersen C; Ge H; Moran SA; Shepherd GM; James WP;
    Diabetes Obes Metab; 2010 Jan; 12(1):26-34. PubMed ID: 19758358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluoxetine: a randomized clinical trial in the treatment of obesity.
    Goldstein DJ; Rampey AH; Enas GG; Potvin JH; Fludzinski LA; Levine LR
    Int J Obes Relat Metab Disord; 1994 Mar; 18(3):129-35. PubMed ID: 8186809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacotherapy for weight loss in patients with type 2 diabetes].
    Toubro S
    Ugeskr Laeger; 2007 Aug; 169(33):2619-22. PubMed ID: 17725907
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of weight reduction on blood pressure in 301 obese patients.
    Schotte DE; Stunkard AJ
    Arch Intern Med; 1990 Aug; 150(8):1701-4. PubMed ID: 2383165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
    Goldstein DJ; Rampey AH; Potvin JH; Masica DN; Beasley CM
    J Clin Psychiatry; 1993 Aug; 54(8):309-16. PubMed ID: 8253699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    Dastjerdi MS; Kazemi F; Najafian A; Mohammady M; Aminorroaya A; Amini M
    Int J Obes (Lond); 2007 Apr; 31(4):713-7. PubMed ID: 16969361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
    Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
    Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group.
    Arch Intern Med; 1997 Mar; 157(6):657-67. PubMed ID: 9080920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a high nutrient density diet on long-term weight loss: a retrospective chart review.
    Sarter B; Campbell TC; Fuhrman J
    Altern Ther Health Med; 2008; 14(3):48-53. PubMed ID: 18517106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
    Kipnes MS; Hollander P; Fujioka K; Gantz I; Seck T; Erondu N; Shentu Y; Lu K; Suryawanshi S; Chou M; Johnson-Levonas AO; Heymsfield SB; Shapiro D; Kaufman KD; Amatruda JM
    Diabetes Obes Metab; 2010 Jun; 12(6):517-31. PubMed ID: 20518807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
    Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
    Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexfenfluramine treatment of obesity: a double blind trial with post trial follow up.
    O'Connor HT; Richman RM; Steinbeck KS; Caterson ID
    Int J Obes Relat Metab Disord; 1995 Mar; 19(3):181-9. PubMed ID: 7780494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.